MRK Merck & Co., Inc. Insider Trading

MRK CMO Guindo Chirfi sold 10,000 shares at $121.46; holds 60,615 post-transaction with 2 prior MRK sells in 4 days.

Guindo Chirfi, Chief Marketing Officer at Merck & Co., Inc., executed a sale of 10,000 shares on 2026-02-12 at $121.46 per share, totaling $1,214,562.00, reducing his holdings from 70,615 shares to 60,615 shares. This transaction is the third MRK sale within a 7-day window (prior sells on 2026-02-09 and 2026-02-05), suggesting concentrated portfolio activity at the CMO level over a brief period. The transaction occurred near the 52-week high of $121.93, with the stock having appreciated 10.1% over 30 days and 28.3% over 90 days. Merck's fundamentals remain solid (revenue $17.3B, net income $5.8B, annual growth +6.7%, P/E 15.55), and the current price of $119.24 sits only 2.2% below the 52-week high, suggesting no obvious deterioration in the company's market standing at the time of sale. The clustering of three insider sales in rapid succession warrants observation of whether this reflects a structured divestment plan or discretionary positioning decisions.

MRK: EVP/President Li Dean Y sold 10,235 shares at $117.52 on 2026-02-10, reducing holdings to 92,035 shares

Li Dean Y, Executive VP & President, sold 10,235 shares of Merck & Co., Inc. at $117.52, representing a -10.0% reduction in his holdings from 102,270 to 92,035 shares. The sale occurred at a price 3.9% below the 52-week high of $121.93, while the stock has appreciated 6.0% over 30 days and 28.1% over 90 days. At MRK specifically, Li's prior sell on 2024-02-09 resulted in a 90-day return of +3.8%, indicating the stock subsequently rose after that sale; his timing pattern at this ticker shows 0 of 1 prior sells were well-timed at the 90-day mark. Merck's fundamentals remain solid with $17.3B quarterly revenue, $5.8B net income, and 6.7% annual revenue growth, alongside a moderate P/E of 15.27.

EVP/General Counsel Zachary Jennifer sells 121,573 shares for $14,485,690.41, reducing stake 63.8%

Zachary Jennifer, EVP and General Counsel at Merck, executed 3 separate sales on 2026-02-09 totaling 121,573 shares (121.6K shares) for $14,485,690.41 at $119.15 per share, cutting his holdings from 190,488 shares (190.5K shares) to 68,915 shares (68.9K shares)—a 63.8% reduction. The sales occurred near the 52-week high (current price $117.65 is -3.5% from the 52-week high of $121.93), and the company's fundamentals remain solid with $17,276,000,000.00 in quarterly revenue, $5,785,000,000.00 net income, and a P/E of 15.34. Across his cross-ticker track record, Jennifer's 2 prior sells had an average 90d return of -4.5% with a 50.00% well-timed rate; at Merck specifically, his prior 2 sells showed mixed timing (one neutral at 90d, one poorly timed at +1.0% and -10.1%). The combination of a substantial reduction in absolute holdings, execution near 52-week highs, and his inconsistent prior timing at this ticker presents a signal worth monitoring for broader context around executive confidence.

Merck CMO Guindo Chirfi sold 10,000 shares at $118.41 on 2026-02-09, reducing stake to 70,615 shares (-12.4%)

Guindo Chirfi, Chief Marketing Officer of Merck & Co., Inc., executed a sale of 10,000 shares at $118.41 on 2026-02-09 for a total value of $1,184,101.00, reducing his holdings from 80,615 to 70,615 shares. The sale occurred near Merck's 52-week high of $121.93 (within 3.5% of peak), and follows a strong 90-day appreciation of +29.4%, suggesting the asset has appreciated significantly during his holding period. His cross-ticker track record shows only 1 prior open-market sale across all tickers, and the outcome of his same-ticker trade on 2026-02-05 remains unmeasurable at this stage. The transaction's modest scale relative to his total holdings and the absence of a discernible pattern in his sales history make this a routine portfolio adjustment for the organization's top marketing executive.

Smart (SVP Fin.) sells 6,400 shares of MRK for $765,920 at $119.68; reduces holding 43.8% to 8.2K shares

Smart Dalton E. III, Senior Vice President of Finance and Global Controller, executed two separate sales totaling 6,400 shares for $765,920.00 at $119.68 per share on 2026-02-04, reducing his position from 14,604 shares to 8,204 shares—a 43.8% reduction in holdings. The sale occurred at a price of $119.68, while the stock currently trades at $121.93, only 2.25 points above the transaction price and at its 52-week high. Notably, the stock has appreciated 12.3% over the past 30 days and 41.3% over the past 90 days, establishing recent strong momentum. As the company's chief financial controller, Smart's significant portfolio reduction merits observation of whether this disposal reflects a structural change in his conviction or simply portfolio management by an executive with substantial ongoing exposure (post-sale holdings of 8,204 shares).

EVP Richard R. DeLuca sold 37,685 MRK shares at $120.92, reducing holdings by 19.0% to 160,173 shares; stock near 52-week high.

Richard R. DeLuca, EVP and President of Merck Animal Health, sold 37,685 shares for $4,557,024.71, representing a 19.0% reduction in his holdings. The sale occurred at $120.92, just 0.0% below the current 52-week high of $121.93, and follows a sharp 12.3% gain over 30 days and 41.3% gain over 90 days. Examined across his prior three MRK sales (all in 2023), two resulted in negative 90-day subsequent returns, meaning he sold ahead of declines—a 66.67% well-timed rate on his cross-ticker history. The current sale at the 52-week high against the backdrop of his prior pattern of sales before pullbacks warrants attention, though Merck's fundamentals remain solid with $17.3B quarterly revenue, $5.8B net income, and a P/E of 15.90.

Merck CEO Davis sells 47.4K shares for $5.6M amid 12.3% monthly rally; post-sale holdings 443.6K

Robert M Davis, Chairman, CEO & President of Merck & Co., Inc., executed two separate open-market sales on 2026-02-04, selling 14,972 shares at $117.38 and 32,462 shares at $118.35 for a combined $5,599,327.27 at a blended average price of $118.04. This reduces his post-transaction holdings to 443.6K shares, representing a -9.7% reduction from his pre-transaction position of 491.0K shares. The sales occurred during a period of significant price appreciation: the stock is currently at $121.93, up 12.3% over the prior 30 days and 41.3% over 90 days, now at the top of its 52-week range. Historically at Merck, Davis's prior four sales (2023–2024) showed a 1-in-4 rate of well-timed exits at the 90-day mark, with mixed returns: three sales were followed by positive 90-day returns (+2.3% to +2.8%), suggesting the stock generally moved higher after his prior sales at this ticker. The company maintains solid fundamentals with $17.3B quarterly revenue, $5.8B net income, and a P/E of 15.90.

CMO Guindo Chirfi sold 20,000 MRK shares at $121.88 for $2.4M, reducing holdings by 19.9%

Guindo Chirfi, Chief Marketing Officer of Merck & Co., sold 20,000 shares (20.0K shares) for $2,437,676.00 ($2.4M) on 2026-02-05 at $121.88, reducing his post-transaction holdings to 80,615 shares (80.6K shares) from a pre-transaction level of 100,615 shares (100.6K shares). The sale occurred while MRK was trading near its 52-week high of $121.93, with the stock up 12.3% over the prior 30 days and 41.3% over 90 days, suggesting a period of strong recent performance. Merck's fundamentals remain solid, with trailing quarterly revenue of $17,276,000,000.00 ($17.3B), net income of $5,785,000,000.00 ($5.8B), a P/E of 15.90, and a market cap of $302,633,007,814.48 ($302.6B). The 19.9% reduction in Chirfi's position represents a material but not complete liquidation of his holdings, occurring within the context of broad-based stock strength rather than a deteriorating operating environment.

Merck EVP Li Dean Y sold 15,087 shares at $118.77 on 2026-02-04, reducing holdings to 102,270 shares (12.9% decrease).

Li Dean Y, Executive VP & President of Merck & Co., executed an open-market sale of 15,087 shares for $1,791,824.15 at $118.77, trimming his position by 12.9% to 102,270 shares post-transaction. The stock has since appreciated to $121.93 (current price), up 0.0% from its 52-week high of $121.93, and has risen 12.3% over the past 30 days and 41.3% over the past 90 days. His prior sell at this ticker on 2024-02-09 occurred in a context where the stock subsequently returned +3.8% over 90 days, indicating the prior sale was not well-timed; across his broader cross-ticker trading history, his one prior sell recorded a 90-day well-timed rate of 0.00%, showing no pattern of prescient exit timing. Merck's fundamentals remain solid with $17.3B in latest quarterly revenue, $5.8B net income, 6.7% annual revenue growth, a P/E of 15.90, and a market cap of $302.6B, suggesting the sale occurred against a backdrop of stable operational and valuation metrics rather than deteriorating conditions.

CFO Litchfield Caroline sold 41,997 shares of MRK at $119.61 on 2026-02-04; stock now trading at $121.93, near 52-week high.

Litchfield Caroline, EVP & CFO of Merck & Co., Inc., sold 41,997 shares at $119.61, reducing her holdings by -31.8% from 132,189 to 90,192 shares and raising $5,023,311.57. MRK has appreciated +12.3% over 30 days and +41.3% over 90 days, now trading at $121.93, which is at the 52-week high of $121.93. Against this backdrop of substantial recent gains, the sale represents a significant reduction in her concentrated position. Notably, her prior sell at MRK on 2024-02-14 was poorly timed (the stock gained +2.5% over the ensuing 90 days), and her cross-ticker track record shows 0 of 1 prior sales were well-timed at the 90-day mark with an average 90-day return of +2.5% after sells. The company's fundamentals remain solid with annual revenue growth of +6.7% and a P/E of 15.90, though the timing of this sale at near 52-week highs after significant near-term appreciation warrants attention to whether the CFO sees valuation headwinds.